NCT06161558 2025-07-16
Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Withdrawn
National Institutes of Health Clinical Center (CC)
University of Oklahoma
Case Comprehensive Cancer Center
Center Trials & Treatment
Arog Pharmaceuticals, Inc.
Pfizer